This is the authors' abstract. We don't add key points for this paper.
Background: Ulcerative colitis (UC) is a relapsing–remitting inflammatory disorder of the colonic mucosa in which loss of epithelial barrier integrity, mitochondrial and metabolic stress, and dysregulated mucosal cytokine networks act together to sustain inflammation. Growth differentiation factor-15 (GDF-15), extracellular nicotinamide phosphoribosyltransferase (eNAMPT/visfatin) and interleukin-22 (IL-22) each sit at the interface between cellular stress, innate immune activation and epithelial repair, but they have not previously been assessed together in an Iraqi UC cohort alongside a panel of circulating barrier markers. Objectives: To measure serum GDF-15, eNAMPT and IL-22 in patients with UC and in healthy controls; to relate them to clinical, endoscopic and biochemical indices of disease activity; to examine their relationship with circulating and urinary markers of intestinal barrier failure; and to evaluate their diagnostic performance individually and as a combined panel. Patients and Methods: This case–control study was conducted at Al-Kadhimiya Teaching Hospital, Baghdad, Iraq, between 1 October 2024 and 1 June 2025. Ninety adults with endoscopically and histologically confirmed UC and forty-five age-, sex- and body-mass-index-matched healthy controls were enrolled. Disease extent was classified by the Montreal system and activity by the total Mayo score. Serum GDF-15, eNAMPT, IL-22, zonulin, intestinal fatty acid-binding protein (I-FABP), lipopolysaccharide (LPS) and LPS-binding protein (LBP), together with urinary claudin-3, were quantified by enzyme-linked immunosorbent assay. Fecal calprotectin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), haemoglobin and albumin were measured by routine laboratory methods. Group comparisons, Spearman correlations, receiver operating characteristic (ROC) analysis and multivariable logistic regression were applied. Results: All three index biomarkers were markedly higher in patients than controls: GDF-15 1186 (742–1890) versus 468 (352–610) pg/mL, eNAMPT 6.84 ± 2.31 versus 2.47 ± 0.86 ng/mL and IL-22 47.6 (28.3–82.1) versus 14.2 (9.8–20.5) pg/mL (all P < 0.001), as were every barrier marker examined. GDF-15 and eNAMPT rose stepwise across remission, mild, moderate and severe disease, whereas IL-22 peaked in moderate disease (72.8 pg/mL) and fell in severe disease (55.1 pg/mL). GDF-15 and eNAMPT correlated strongly with the total Mayo score (r = 0.72 and r = 0.68), the Mayo endoscopic subscore, fecal calprotectin and CRP, and moderately with zonulin, I-FABP and LPS; IL-22 showed consistently weaker correlations with barrier markers. For discriminating UC from controls the area under the curve (AUC) was 0.91 for GDF-15, 0.93 for eNAMPT and 0.87 for IL-22, rising to 0.97 for the three-marker panel; for active versus quiescent disease the panel achieved an AUC of 0.93. After adjustment for age, sex, disease extent and therapy, GDF-15 (adjusted odds ratio [aOR] 2.68 per 500 pg/mL), eNAMPT (aOR 1.52 per 1 ng/mL) and zonulin (aOR 1.38 per 10 ng/mL) remained independently associated with active disease, while IL-22 lost significance (aOR 1.14, P = 0.28). Conclusions: GDF-15 and eNAMPT behave as activity-tracking, barrier-linked biomarkers in Iraqi patients with UC and retain independent associations with active disease after multivariable adjustment, whereas IL-22 behaves as a non-linear, reparative cytokine whose serum concentration peaks at intermediate disease severity. A three-marker panel substantially outperforms any single analyte and merits prospective validation as a non-invasive adjunct to endoscopy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ghassan Nissan (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: